Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS). Inebilizumab (formerly MEDI-551) binds to and depletes CD19 B cells.
Objectives: To assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of inebilizumab in adults with relapsing MS.
Methods: This phase 1 trial randomised 28 patients 3:1 (21, inebilizumab; 7, placebo) to inebilizumab (2 intravenous (IV) doses, days 1 and 15: 30, 100 or 600 mg; or single subcutaneous (SC) dose on day 1: 60 or 300 mg) or matching placebo, with follow-up until at least week 24 or return of CD19 B-cell count to ⩾80 cells/µL.
Results: Complete B-cell depletion was observed across all doses. Infusion/injection (grade 1/2) reactions occurred in 6/15 patients receiving inebilizumab IV, 2/5 placebo IV and 1/6 inebilizumab SC. Serious adverse events occurred in three patients receiving inebilizumab: pyrexia, mixed-drug intoxication (unrelated to inebilizumab; resulted in death) and urinary tract infection. Mean number of cumulative new gadolinium-enhancing lesions over 24 weeks was 0.1 with inebilizumab versus 1.3 with placebo; mean numbers of new/newly enlarging T2 lesions were 0.4 and 2.4, respectively.
Conclusion: Inebilizumab had an acceptable safety profile in relapsing MS patients and showed a trend in reductions in new/newly enlarging and gadolinium-enhancing lesions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360486 | PMC |
| http://dx.doi.org/10.1177/1352458517740641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inebilizumab shows promise for IgG4-RD.
Nat Rev Rheumatol
December 2024
Nature Reviews Rheumatology, .
Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.
Neurol Neuroimmunol Neuroinflamm
January 2025
From the Department of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology (A.D., L.C., J.J.-W.C., B.G.W., S.A.B., S.J.P., E.P.F.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurosciences (A.D.), Biomedicine, and Movement Sciences, University of Verona, Italy; Department of Radiology (K.N.K.), Mayo Clinic; Department of Ophthalmology (J.J.-W.C.), Mayo Clinic College of Medicine, Rochester, MN; Department of Neurology (D.M.W., C.V.-S.), Mayo Clinic, Scottsdale, AZ; Department of Neurology (B.G.W.), University of Virginia, Charlottesville; Department of Neurology (A.S.L.-C.), Mayo Clinic College of Medicine, Jacksonville, FL; Neurology Unit (E.S.), University Hospital of Sassari, Italy; and Department of Laboratory Medicine and Pathology (S.J.P., E.P.F.), Mayo Clinic College of Medicine, Rochester, MN.
Objectives: To characterize the frequency and clinicoradiologic phenotype of cerebellar involvement in attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) which are incompletely captured in current diagnostic criteria.
Methods: Brain MRI scans from patients with AQP4+NMOSD in the Mayo Clinic database were reviewed, and those with cerebellar T2-hyperintense lesions ≤30 days from attack onset were included for clinical and radiologic characterization.
Results: From 432 patients with AQP4+NMOSD, we identified 17 (4%) with cerebellar attacks.
First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.
CNS Neurosci Ther
November 2024
Department of Neurology, Huashan Hospital, Fudan University and Institute of Neurology, Fudan University, Shanghai, China.
Article Synopsis
- NMOSD is a rare autoimmune disease affecting the CNS, and this study is the first Phase I clinical trial in Chinese patients testing the safety and efficacy of a new drug called BAT4406F, an anti-CD20 monoclonal antibody.
- The study involved 15 patients who received different doses of BAT4406F, with results showing no dose-limiting toxicities and mostly mild side effects, indicating a favorable safety profile.
- The drug demonstrated effective B-cell depletion, important for treating NMOSD, with a nonlinear pharmacokinetic profile and longer elimination half-life, suggesting promising therapeutic potential.
Linking Downbeat Nystagmus and Aquaporin-4-Positive Neuromyelitis Optica: A Closer Look at Their Hidden Relationship.
Cureus
October 2024
Neuro-ophthalmology, Department of Clinical Sciences, Florida State University College of Medicine, Tallahassee, USA.
Neuromyelitis optica (NMO), an autoimmune disease, typically presents with loss of vision and myelopathic signs. NMO may be associated with antibodies selective for aquaporin-4 (AQP4), a water channel located within the optic nerves and spinal cord.AQP4 is distributed in the periventricular region, corpus callosum, magnocellular nuclei of the hypothalamus, and brain stem.
View Article and Find Full Text PDFNeuromyelitis optica spectrum disorder with ultra-longitudinally extensive transverse myelitis: A case report and literature review.
Heliyon
November 2024
Neurology Department, Central Hospital of Dalian University of Technology(Dalian Municipal Central Hospital), Dalian City, 116000, China.
Article Synopsis
- * A unique case of a patient with NMOSD presented ultra-LETM alongside connective tissue disorders, treated with high-dose medications and a sequence of disease-modifying therapies, leading to significant recovery.
- * Early evaluation of autoimmune diseases and prompt treatment are vital for improving outcomes in NMOSD patients presenting with u-LETM as an initial symptom.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!